Research programme: cytomegalovirus DNA polymerase inhibitors - PharmaciaAlternative Names: Cytomegalovirus DNA polymerase inhibitors research programme - Pharmacia
Latest Information Update: 02 Aug 2002
At a glance
- Originator Pharmacia Corporation
- Mechanism of Action DNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 04 May 2000 New profile
- 04 May 2000 Preclinical development for Cytomegalovirus infections in USA (Unknown route)